AB Sciex. (4/19/11). "Press Release: Singapore Eye Research Institute Performs Breakthrough Research on Chronic Inflammatory Eye Conditions with AB Sciex TripleTOF 5600 System". Framingham, MA.

	Region	Singapore
	Organisation	AB Sciex (Danaher)
	Group	Danaher (Group)
	Product	AB Sciex TripleTOF™ 5600 System
	Person	Hicks, Dave (Danaher 201004 VP + General Manager Pharmaceuticals + Proteomics at AB SCIEX)
	Person 2	Petrucci, Anthony (AB SCIEX 201003 Corporate Communications)

Goal to develop a clinical test to better treat dry eye and improve understanding of the effects of contact lenses on the health of the eye

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute (SERI), an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOFTM 5600 System. SERI plans to use the data from the TripleTOFTM system to accelerate the process to develop a clinical test to significantly improve understanding of inflammation of the eye. This information is expected to be invaluable in helping SERI develop methods with measurable end-points for improved diagnosis and pharmacological treatments of dry eye and other eye conditions that affect millions of people across the world.

Objective clinical tests to accurately measure the severity of dry eye syndrome and preclinical evaluation of new pharmacological therapies currently do not exist. As a leader in ocular proteomics studies, SERI is advancing eye research by identifying and verifying six biomarker candidates that are associated with dry eye syndrome. The institute is collaborating with Allergan, an ocular pharmaceutical company, to conduct a clinical trial with hundreds of patient samples to validate early data that these biomarkers show an accuracy rate close to 100 percent whether a person has dry eye.

SERI selected the AB SCIEX TripleTOFTM 5600 System for this important research because of the system's high throughput and high sensitivity coupled with high resolution and accurate mass. SERI is also using the Eksigent nanoLC-Ultra and cHiPLC-nanoflex chromatography technology to increase productivity and improve reproducibility. The researchers can utilize these technologies to generate better quality information from samples more easily than previously possible. With the TripleTOFTM system, SERI is expecting to complete the clinical trials in less than half the time it would take using other systems to collect research data.

Determining how the delicate epithelial cells on the surface of the cornea are affected by contact lenses is also not as well-understood as it could be, so the TripleTOFTM 5600 System, which provides high-performance quantitative and qualitative analysis with accurate mass, will be used for advanced metabolic research studies of contact lens wear. By studying the metabolomics of contact lens wear, the SERI researchers will be able to better understand how the cells on the surface of the cornea are affected by the type of lens as well as the length of time wearing the lens.

The SERI research team, led by Dr. Roger Beuerman, Ph.D. and his colleague Zhou Lei, Ph.D., is also pushing the limits of eye research by utilizing the AB SCIEX and Eksigent technologies to reveal new insights into the understanding of disease processes. This advanced eye research program demonstrates the commitment to continued progress and breakthrough developments at SERI, which is part of a large hospital group called SingHealth. Support from Dr. Tan Ser Kiat, Group CEO, Dr. Donald Tan, MD of Singapore National Eye Center and the Singhealth Foundation to accomplish the research team's goals has been critical. Also supporting the research at SERI is AB SCIEX Global Service whose world-class service was a factor in SERI's decision to choose AB SCIEX.

Roger Beuerman, Ph.D, Head of the Proteomics Research Group and Senior Scientific Director at the Singapore Eye Research Institute, and Professor at the Duke-NUS Medical School in Singapore

"New innovations in the diagnosis and measurement of the response to treatment of chronic eye conditions offer hope to all the millions of patients who suffer from these eye diseases. Our eye research institute invested in leading-edge technology to boost our capabilities to improve the understanding of eye diseases and speed up development of new ways to treat these conditions. The AB SCIEX TripleTOFTM 5600 System is a strategic tool for us to accomplish our goals with the versatility of both large and small molecule analysis, ultimately intended to improve people's quality of life."

Dave Hicks, Vice President and General Manager of the Pharmaceutical and Proteomics Business, AB SCIEX

"The use of TripleTOFTM 5600 for eye research is another example of how AB SCIEX technology is used across an increasingly wide variety of applications. Our customers, such as the researchers at the Singapore Eye Research Institute, trust us to deliver innovative tools and scientific expertise that help them achieve what they set out to do as they push the limits of biomedical research. With our recent advancements in mass spectrometry technology, the possibilities for breakthrough research have never been greater."

Media Resources

AB SCIEX mass spectrometry portfolio
Eksigent portfolio

About AB SCIEX

AB SCIEX is a global leader in the development of life science analytical technologies that help answer complex scientific challenges. The company provides scientific instrumentation, software and services used to discover new drugs, advance medical science and protect the food supply and the environment. AB SCIEX technology solutions combine the highest performance with the highest reliability to enable our customers to fuel scientific discovery, deliver results with confidence and improve the quality of life. The company has a more than 20-year history of innovation and market leadership as the former Applied Biosystems/MDS Analytical Technologies joint venture. For more information about AB SCIEX, go to www.absciex.com. Follow AB SCIEX on Twitter @ABSCIEX and on Facebook.

For Research Use Only. Not for use in diagnostic procedures. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEXTM is being used under license.

Media Contact

Anthony Petrucci
Public Relations
508.383.7961
anthony.petrucci@absciex.com

##END##

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

AB Sciex. (4/19/11). "Press Release: Singapore Eye Research Institute Performs Breakthrough Research on Chronic Inflammatory Eye Conditions with AB Sciex TripleTOF 5600 System". Framingham, MA.

More documents for Danaher (Group)